Recombinant adenovirus (Adv), a replication-defective adenoviral vector system, is widely used for gene delivery in most cell types. The adenoviral vectors provided by Genemedi are based on human adenovirus type 5 (Ad5), which is replication-incompetent (-E1/-E3) and can’t be integrated into host genome, guaranteeing the security for subsequent operations. Adv packaging by Genemedi shows almost 100% gene delivery in most cell types in the recombinant protein expression system both in vivo and in vitro. Derived from the type II CRISPR-Cas bacterial adaptive immune system, Cas9, an RNA-guided endonuclease, has emerged as a versatile genome-editing platform. Several microbial species possess this system, among which, Streptococcus pyogenes Cas9 (SpCas9), is the most robust and widely used Cas9 to date, primarily recognizes NGG PAMs and is consequently restricted to sites that contain this motif. By combining Adv packaging system with Cas9 genome-editing platform, Genemedi has further developed Adv-Cas9 system to achieve gene knockout with high efficiency, which is one of the top advanced gene knockout technology in the world.